It certainly removes having to have a pill bottle in your purse or ... These results could help to determine availability of lenacapavir as PrEP in the future. 2 1. Gilead presents additional ...

unlike daily oral pills, and addresses a broad population. Lenacapavir is already approved under the brand name Sunlenca in the United States for the treatment of HIV-1 infection in heavily ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse ...

A bi-annual injectable treatment for HIV prevention (PrEP), Lenacapavir, is being celebrated as a major advancement in the field. This followed new study results that showed a 96 per cent ...

The treatment combines MSD’s islatravir, an experimental nucleoside reverse transcriptase inhibitor, with Gilead’s lenacapavir ... make Gilead and MSD’s new pill an attractive alternative ...

And when compared to the F/TDF prevention pill, the injection reduced HIV infections by 89%. Among the 3 265 participants enrolled in the study, 11 people acquired HIV- two of the 2 179 people who ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor ...

This translated to HIV incidence of 0.93 per 100 person years in the prevention pill arm compared to only 0.1 per 100 person years in the lenacapavir arm. This was compared to the background ...